Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	97
Overall Study	STARTED	Candesartan 32 mg	465
Overall Study	STARTED	HCT 25 mg	470
Overall Study	STARTED	Candesartan/HCT 32/25 mg	492
Overall Study	COMPLETED	Placebo	90
Overall Study	COMPLETED	Candesartan 32 mg	457
Overall Study	COMPLETED	HCT 25 mg	461
Overall Study	COMPLETED	Candesartan/HCT 32/25 mg	478
Overall Study	NOT COMPLETED	Placebo	7
Overall Study	NOT COMPLETED	Candesartan 32 mg	8
Overall Study	NOT COMPLETED	HCT 25 mg	9
Overall Study	NOT COMPLETED	Candesartan/HCT 32/25 mg	14

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00434967/flow